First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. AMC
4. NVDA
5. NUAI
6. MSFT
7. ACN
8. FFAI
9. PAA
10. TLT

Go back to First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Merck & Co. (NYSE: MRK) Delayed: 148.39 +1.52 (1.03%)
Previous Close $146.87    52 Week High $65.46 
Open $146.79    52 Week Low $47.97 
Day High $148.40    P/E 100.95 
Day Low $145.60    EPS $1.47 
Volume 390,730